Quotient Sciences Acquires Arcinova

Read the press release here

"Throughout my career I have always been passionate about providing drug discovery and development services to customers. I gain a great deal of satisfaction from collaborating with biotechnology and pharmaceutical companies and being part of a team who deliver solutions that are often of critical importance to our partners."

Mark Chadwick

Originally a molecular biologist, Mark has spent 18 years in the drug discovery and development industry in both project management and commercial roles. Previous relevant positions include CEO at AIM-listed Physiomics plc, VP Business Development at Excelsyn and Director of Commercial Operations at BioFocus. 

Mark holds a degree in Genetics from the University of Nottingham, a PhD in Molecular Biology from the University of Newcastle and an MBA from Imperial College London.

"Throughout my career I have always been passionate about providing drug discovery and development services to customers. I gain a great deal of satisfaction from collaborating with biotechnology and pharmaceutical companies and being part of a team who deliver solutions that are often of critical importance to our partners."